PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA) from its SEC filings: 2023 revenue $42.8 million (+65% vs the year before), net margin 44%, free cash flow -$13.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2023) | $42.8 million |
| Revenue growth | +65% |
| Net income | $18.7 million |
| Net margin | 43.7% |
| Free cash flow | -$13.9 million |
| Diluted EPS | $2.17 |
| Latest quarter (Q3 2024 (calendar)) revenue vs a year earlier | -100% |
| Cash | $187.8 million |
| Share count, 1 year | +30% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.